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Background: Association of monocyte chemoattractant protein 1 (MCP-1), an inflammatory factor, with stroke has not been studied in a large 
cohort. We measured plasma MCP-1 (1 of 13 biomarkers, no adjustment for multiple testing) in the Stroke Prevention by Aggressive Reduction in 
Cholesterol Levels (SPARCL) trial, that compared atorvastatin 80 mg/d (ATV) to placebo (PLB) on the risk of stroke and major coronary events (COR: 
cardiac death or MI) in patients with recent stroke or transient ischemic attack but no coronary heart disease.
Methods: Baseline MCP-1 was measured in 1237 of 2366 PLB and 1144 of 2365 ATV patients. Time to recurrent stroke or first COR was evaluated 
by Cox proportional hazard models for quartiles of MCP-1 without and with adjustment for age, gender, smoking, diabetes, entry event, time since 
entry event, and geographic region.
Results: The median follow-up was 4.9 years. With quartile 1 (Q1) of ATV as the reference for all quartiles, Q4 of MCP-1 weakly associated with 
increased risk for secondary stroke in both ATV and PLB and this association was lost after adjusting for covariates (Table). In contrast, Q4 of MCP-1 
strongly associated with increased risk for first COR in both PLB and ATV-treated patients even after covariate adjustment. ATV did not alter the risk 
associated with Q4.
Conclusion: MCP-1 levels identify the risk of initial major coronary events, but not that of secondary stroke. These data suggest MCP-1 contributes 
more to adverse events in the coronary than cerebral circulation.
Clinical Endpoint
Ref group: ATV 
Quartile 1 (n=299)
PLB, Quartile 4 (n=289) ATV, Quartile 4 (n=302)
HR 95% CI P HR 95% CI P
Stroke
Unadjusted 1.389 0.972, 1.985 0.0716 1.422 1.000, 2.022 0.0497
Adjusted 1.165 0.808, 1.679 0.4131 1.229 0.862, 1.752 0.2552
Major coronary
Unadjusted 3.188 1.651, 6.157 0.0006 3.132 1.626, 6.033 0.0006
Adjusted 2.800 1.443, 5.430 0.0023 2.777 1.436, 5.371 0.0024
